Skip to search formSkip to main contentSkip to account menu

Sarasar

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lonafarnib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Current available therapies and future directions in the treatment of malignant gliomas
The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing… 
Review
2006
Review
2006
Farnesyltransferase inhibitors in myelodysplastic syndrome
The farnesyltransferase inhibitors (FTIs) are in active clinical development in a variety of human malignancies. The most… 
2006
2006
SCH66336 (Sarasar®), an oral farnesyl transferase inhibitor, synergizes with temozolomide and radiation therapy for orthotopic malignant gliomas
3798 Background: Malignant gliomas are highly lethal tumors that display resistance to current therapies. The best treatment… 
Review
2005
Review
2005
Farnesyltransferase inhibitors in myelodysplastic syndrome.
The farnesyltransferase inhibitors (FTIs) are in active clinical development in a variety of human malignancies. The most… 
Review
2004
Review
2004
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Farnesyltransferase (FT) inhibitors were originally designed as anticancer agents, and were thought to act by inhibiting the… 
2004
2004
Phase I trial of the oral farnesyl protein transferase inhibitor lonafarnib (SCH66336): A Pediatric Brain Tumor Consortium (PBTC) study.
1517 Background: Children with recurrent or progressive central nervous system (CNS) tumors after optimal up-front therapy have a… 
2004
2004
92 A phase I, pharmacological and biological study of Sarasar® (Ionafarnib, SCH 66336), cisplatin and gemcitabine in patients with advanced solid tumors
2004
2004
Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.
Review
2003
Review
2003
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials… 
2002
2002
Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
An international meeting focused on farnesyl transferase inhibitors (FTIs) was held in Naples on 12 April 2002 and represented an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)